31 research outputs found
Loss of NOS1 expression in high-grade renal cell carcinoma associated with a shift of NO signalling
Nephrogenic adenoma associated with cytomegalovirus infection of the ureter in a renal transplant patient: presentation as ureteral obstruction
Compara??o da efic?cia de losartana, hidrocortisona e ?cido acetilsalic?lico (AAS) na preven??o do desenvolvimento de tecido cicatricial fibroso nos m?sculos esquel?ticos.
Objective: To analyze fibrous scar tissue inhibition capacity with the use of losartan, hydrocortisone and
acetylsalicylic acid. Method: The sample consisted of 120 male heterogeneic Wistar rats with a muscle laceration
model. The rats were divided into four groups of 30 animals each: control group, losartan group, ASA group and
hydrocortisone group. The animals were anesthetized and a 2.5 cm longitudinal incision was made in the left
thoracolumbar paravertebral region. The muscles were subjected to a Grade III lesion caused by applying Kelly
hemostatic forceps for 60 seconds, followed by sectioning with scissors. The skin was sutured with 3-0 nylon
monofilament thread. The animals were placed in individual cages with plenty of food and water. The losartan
group received losartan diluted in water at a dose of 0.1 mg/mL (10 mg/kg/day), the ASA Group received a 3
mg/mL ASA solution (300 mg/kg/day), and the hydrocortisone group received a 0.2 mg/mL hydrocortisone
solution (20 mg/kg/day). Results: The control, losartan, hydrocortisone and aspirin groups had a fibrotic area of
0.95 ? 0.35 mm, 0.55 ? 0.34 mm, 0.93 ? 0.33 mm, and 0.66 ? 0.36 mm, respectively. We observed a significantly
smaller fibrotic area in the losartan group compared to the control (p=0.01) and hydrocortisone (p=0.01) groups.
There were no significant differences among the other groups. Conclusion: The healing of striated skeletal
muscle produced less fibrous scar tissue when exposed to losartan in comparison to the control group or the
hydrocortisone group. Level of Evidence I; Randomized double-blind placebo-controlled study.Objetivo: Analisar a capacidade de inibi??o de forma??o de tecido cicatricial fibroso com losartana, hidrocortisona e AAS. M?todos: A amostra consistiu em 120 ratos Wistar heterog?nicos machos com modelo de lacera??o
muscular. Os ratos foram distribu?dos em quatro grupos de 30 animais: grupo controle, grupo losartana, grupo
AAS e grupo hidrocortisona. Os animais foram anestesiados e submetidos a uma incis?o em sentido longitudinal
de 2,5 cm de extens?o na regi?o paravertebral toracolombar esquerda, e os m?sculos sofreram uma les?o grau III
com pin?a hemost?tica de Kelly durante 60 segundos e posterior sec??o com tesoura. A pele foi suturada com nylon
monofilamentar 3-0. Os animais foram colocados em gaiolas individuais, com ?gua e alimento ? vontade. O grupo
losartana recebeu losartana dilu?da em ?gua na dose de 0,1 mg/ml (10 mg/kg/dia), o grupo AAS recebeu solu??o
de AAS 3 mg/ml (300 mg/kg/dia), o grupo hidrocortisona recebeu solu??o de hidrocortisona 0,2 mg/ml (20 mg/kg/
dia). Resultados: Os grupos controle, losartana, hidrocortisona e AAS apresentaram ?rea fibr?tica de0,95 ? 0,35 mm,
0,55 ? 0,34 mm, 0,93 ? 0,33 mm, 0,66 ? 0,36 mm, respectivamente. Observou-se ?rea fibr?tica significativamente
menor do grupo losartana em compara??o com o grupo controle (p = 0,01) e hidrocortisona (p = 0,01). Nos demais
grupos n?o houve diferen?a significativa. Conclus?o: A cicatriza??o do m?sculo estriado esquel?tico produziu menos
tecido cicatricial fibroso quando exposto ? losartana do que quando comparado com o grupo controle ou o grupo
hidrocortisona. N?vel de Evid?ncia I; Estudo duplo-cego randomizado controlado por placebo